JEREMY ROCKWELL: Open Payments
NPI 1952942310 · PAWTUCKET, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,289 in 37 payments from 9 companies in 2025. Trend: 2023 $245 · 2024 $534 · 2025 $1,289
Food & beverage: $1,289
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 13 | $346 |
| Teva Pharmaceuticals USA, Inc. | 7 | $268 |
| Janssen Pharmaceuticals, Inc | 5 | $190 |
| Neurocrine BioSciences, Inc. | 3 | $162 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $125 |
| E.R. Squibb & Sons, L.L.C. | 4 | $90 |
| Indivior Inc. | 2 | $59 |
| Alkermes, Inc. | 1 | $34 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $14 |
Products named: REXULTI, INGREZZA, UZEDY, ABILIFY MAINTENA, CAPLYTA, INVEGA SUSTENNA, AUSTEDO XR, COBENFY.
Industry payments across RI — which companies pay providers there.
